CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...
Phase 1
Seoul, Korea, Republic of and 20 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Seoul, Korea, Republic of and 89 other locations
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....
Phase 1, Phase 2
Seoul, Seoul, South Korea
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Seoul, Korea, Republic of and 60 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 74 other locations
receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non...
Phase 1
Seoul, Korea, Republic of and 26 other locations
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...
Phase 1
Seoul, Korea, Republic of and 18 other locations
bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...
Phase 1
Seoul, Korea, Republic of and 28 other locations
ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...
Phase 1, Phase 2
Seoul, Korea, Republic of and 23 other locations
participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...
Phase 3
Seoul, Korea, Republic of and 52 other locations
Clinical trials
Research sites
Resources
Legal